TRAJENTA DUO 2.5 MG 1000 MG Israel - engelska - Ministry of Health

trajenta duo 2.5 mg 1000 mg

boehringer ingelheim israel ltd. - linagliptin; metformin hydrochloride - film coated tablets - linagliptin 2.5 mg; metformin hydrochloride 1000 mg - metformin - as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate. trajenta-duo should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. trajenta-duo has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using trajenta-duo.

Linagliptin Viatris Irland - engelska - HPRA (Health Products Regulatory Authority)

linagliptin viatris

viatris limited - linagliptin - film-coated tablet - linagliptin

TRAJENTA linagliptin 5 mg film-coated tablet blister pack Australien - engelska - Department of Health (Therapeutic Goods Administration)

trajenta linagliptin 5 mg film-coated tablet blister pack

boehringer ingelheim pty ltd - linagliptin, quantity: 5 mg - tablet, film coated - excipient ingredients: mannitol; pregelatinised maize starch; maize starch; copovidone; magnesium stearate; titanium dioxide; hypromellose; purified talc; macrogol 6000; iron oxide red - trajenta is indicated in adult patients with type 2 diabetes mellitus to improve glycaemic control in conjunction with diet and exercise,,- as monotherapy when metformin and sulfonylureas are not tolerated, or are contraindicated, or,- as add on to metformin, sulfonylureas or metformin plus sulfonylureas, or to insulin (with or without metformin) or,- as add on to metformin plus sglt2 inhibitors.

Linagliptin PharOS 5 mg film-coated tablets Malta - engelska - Malta Medicines Authority

linagliptin pharos 5 mg film-coated tablets

pharos – pharmaceutical oriented services limited lesvou str. (end), thesi loggos, industrial zone, 144 52 metamorfossi attikis,, greece - film-coated tablet - linagliptin 5 mg - drugs used in diabetes

TRAJENTA  DUO  2.5 MG 500 MG Israel - engelska - Ministry of Health

trajenta duo 2.5 mg 500 mg

boehringer ingelheim israel ltd. - linagliptin; metformin hydrochloride - film coated tablets - metformin hydrochloride 500 mg; linagliptin 2.5 mg - metformin - metformin - as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate. trajenta-duo should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. trajenta-duo has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using trajenta-duo.

TRAJENTA DUO  2.5 MG  850 MG Israel - engelska - Ministry of Health

trajenta duo 2.5 mg 850 mg

boehringer ingelheim israel ltd. - linagliptin; metformin hydrochloride - film coated tablets - metformin hydrochloride 850 mg; linagliptin 2.5 mg - metformin - metformin - as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate. trajenta-duo should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. trajenta-duo has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using trajenta-duo.

TRAJENTA DUO  2.5 MG  850 MG Israel - engelska - Ministry of Health

trajenta duo 2.5 mg 850 mg

boehringer ingelheim israel ltd. - linagliptin; metformin hydrochloride - film coated tablets - metformin hydrochloride 850 mg; linagliptin 2.5 mg - metformin - as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate. trajenta-duo should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. trajenta-duo has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using trajenta-duo.

TRAJENTA  DUO  2.5 MG 500 MG Israel - engelska - Ministry of Health

trajenta duo 2.5 mg 500 mg

boehringer ingelheim israel ltd. - linagliptin; metformin hydrochloride - film coated tablets - metformin hydrochloride 500 mg; linagliptin 2.5 mg - metformin - as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate. trajenta-duo should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. trajenta-duo has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using trajenta-duo.

TRAJENTA DUO  2.5 MG  850 MG Israel - engelska - Ministry of Health

trajenta duo 2.5 mg 850 mg

boehringer ingelheim israel ltd. - linagliptin; metformin hydrochloride - film coated tablets - metformin hydrochloride 850 mg; linagliptin 2.5 mg - metformin - as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate. trajenta-duo should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. trajenta-duo has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using trajenta-duo.